EUVIMEDEUVIMED entdecken
Crossref

Effect of Sacubitril–Valsartan on Secondary Mitral Regurgitation and Left Ventricular Reverse Remodeling in Patients With Heart Failure With Reduced Ejection Fraction: A 2D and 3D Echocardiographic Study

Mohammed Ali Mohammed Hammad, Ismael Elbarky, Reda Biomy, Wael Anwar Elshahat Hassib, Khaled Abouelmagd, Mohamed Kamal Ibrahim Salama

Echocardiography · 2026

DOI: 10.1111/echo.70413 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Echocardiography, 2026. Verfasst von Mohammed Ali Mohammed Hammad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Faculty of Medicine, Kafr Elsheikh University, Kafr Elsheikh, Egypt. Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Heart Failure, Ventricular Remodeling, Echocardiography, Three-Dimensional. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Heart failure (HF) with reduced ejection fraction (HFrEF) is characterized by progressive left ventricular (LV) remodeling and is often complicated by secondary (functional) mitral regurgitation (MR). Sacubitril–valsartan (S/V), an angiotensin receptor–neprilysin inhibitor (ARNI), has demonstrated superiority over enalapril in reducing morbidity and mortality in HFrEF. Its mechanism of action includes promoting LV reverse remodeling (LVRR), but the comprehensive effect on both LVRR and secondary MR, particularly using advanced three‐dimensional (3D) echocardiography, requires further elucidation.

Objectives

To evaluate the effect of 1‐year S/V therapy on LVRR and the severity of secondary MR in patients with HFrEF, utilizing both two‐dimensional (2D) and 3D echocardiographic parameters.

Methods

This prospective, single‐center study included 80 patients with HFrEF (LVEF ≤ 40%) initiated on S/V. Comprehensive 2D and 3D transthoracic echocardiography was performed at baseline 6 months, and 1 year of treatment. LVRR was assessed by changes in LV volumes (EDVI, ESVI), LVEF, and LV mass index (LVMI). MR severity was quantified using the effective regurgitant orifice area (EROA). Paired statistical tests ( t ‐test or Wilcoxon signed‐rank test) were used for pre‐ and posttreatment comparisons. Correlation and multivariable linear regression analyses were performed to identify predictors of LVRR.

Results

After 1 year of S/V therapy, patients with HFrEF demonstrated marked and consistent improvements in both MR and (LV) structure and function. EROA decreased from 0.36 ± 0.08 cm 2 to 0.24 ± 0.09 cm 2 (−34.6%, p < 0.001), accompanied by reductions in regurgitant volume (RV) (−32.6%, p < 0.001) and regurgitant fraction (−30.8%, p < 0.001). LVRR was evidenced by significant increases in LVEF (3D: +42.1%, p < 0.001, Cohen's d = 2.63) and reductions in LVEDV (−18.0%, p < 0.001) and LVESV (−31.8%, p < 0.001), as well as a 14.7% decrease in LVMI ( p < 0.001). Correlation analysis revealed that MR improvement closely paralleled LV remodeling, with ΔEROA strongly associated with reductions in LVESVI ( r = 0.774, p < 0.001), LVEDVI ( r = 0.558, p < 0.001), and LVEF improvement ( r = −0.781, p < 0.001). Multivariable regression identified lower baseline LVEF (3D) as the strongest independent predictor of LVRR ( β = −2.304, p < 0.001)

Conclusions

S/V therapy induces significant and comprehensive LVRR and a marked reduction in secondary MR severity in HFrEF patients. The strong correlation between these two effects suggests that MR improvement is primarily driven by LVRR. Lower baseline LVEF is a powerful predictor of the magnitude of LVRR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitral Valve InsufficiencyHeart FailureVentricular RemodelingEchocardiography, Three-DimensionalTetrazolesAminobutyratesEchocardiographyHumansBiphenyl CompoundsDrug CombinationsStroke VolumeFemaleMaleValsartanProspective StudiesTreatment OutcomeAngiotensin Receptor AntagonistsMiddle AgedHeart VentriclesAged

Stichwörter der Autor:innen

3D echocardiographyglobal longitudinal strainheart failure with reduced ejection fractionleft ventricular reverse remodelingsacubitril‐valsartansecondary mitral regurgitation

Substanzen

Biphenyl Compoundssacubitril and valsartan sodium hydrate drug combinationDrug CombinationsTetrazolesAminobutyratesValsartanAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Cardiology, Faculty of Medicine, Kafr Elsheikh University, Kafr Elsheikh, Egypt.
  • Faculty of Medicine, Alexandria University, Kafr Elsheikh, Egypt.
  • Department of Cardiology, Faculty of Medicine-Al Azhar University, New Damietta, Egypt.

Zitieren

APA

Hammad, M. A. M., Elbarky, I., Biomy, R., Hassib, W. A. E., Abouelmagd, K., & Salama, M. K. I. (2026). Effect of Sacubitril–Valsartan on Secondary Mitral Regurgitation and Left Ventricular Reverse Remodeling in Patients With Heart Failure With Reduced Ejection Fraction: A 2D and 3D Echocardiographic Study. Echocardiography. https://doi.org/10.1111/echo.70413

Vancouver

Hammad MAM, Elbarky I, Biomy R, Hassib WAE, Abouelmagd K, Salama MKI. Effect of Sacubitril–Valsartan on Secondary Mitral Regurgitation and Left Ventricular Reverse Remodeling in Patients With Heart Failure With Reduced Ejection Fraction: A 2D and 3D Echocardiographic Study. Echocardiography. 2026. doi:10.1111/echo.70413

BibTeX
@article{Hammad2026,
  author = {Hammad, Mohammed Ali Mohammed and Elbarky, Ismael and Biomy, Reda and Hassib, Wael Anwar Elshahat and Abouelmagd, Khaled and Salama, Mohamed Kamal Ibrahim},
  title = {Effect of Sacubitril–Valsartan on Secondary Mitral Regurgitation and Left Ventricular Reverse Remodeling in Patients With Heart Failure With Reduced Ejection Fraction: A 2D and 3D Echocardiographic Study},
  journal = {Echocardiography},
  year = {2026},
  doi = {10.1111/echo.70413}
}
Kostenlos starten →